You can reach Adam on Signal at stataf.54. Caribou Biosciences is delaying the readout of clinical trials involving its CRISPR T-cell therapies for blood cancer — hoping that longer follow-up ...

Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to prioritize its lead oncology clinical programs, CB-010 and CB-011 ...